Guidelines for development of diagnostic markers in bladder cancer

[1] Birkhahn M(2007)Molecular markers for bladder cancer: the road to a multimarker approach Expert Rev Anticancer Ther 7 1717-1727

[2] Mitra AP(2007)VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival Anticancer Res 27 3127-3133

[3] Cote RJ(2007)Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 79 210-216

[4] Herrmann E(2007)Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target World J Urol 25 581-593

[5] Eltze E(2008)Biological markers in the diagnosis of recurrent bladder cancer: an overview Expert Rev Mol Diagn 8 63-72

[6] Bierer S(2001)Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma J Urol 165 696-697

[7] Köpke T(2001)Urine based markers of urological malignancy J Urol 165 600-611

[8] Görge T(2003)Tumor markers in the diagnosis of primary bladder cancer. A systematic review J Urol 169 1975-1982

[9] Neumann J(2002)Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder Eur Urol 41 34-39

[10] Hertle L(2002)BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder Anticancer Res 22 1157-1160

[1] Birkhahn M(2007)Molecular markers for bladder cancer: the road to a multimarker approach Expert Rev Anticancer Ther 7 1717-1727

[2] Mitra AP(2007)VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival Anticancer Res 27 3127-3133

[3] Cote RJ(2007)Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 79 210-216

[4] Herrmann E(2007)Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target World J Urol 25 581-593

[5] Eltze E(2008)Biological markers in the diagnosis of recurrent bladder cancer: an overview Expert Rev Mol Diagn 8 63-72

[6] Bierer S(2001)Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma J Urol 165 696-697

[7] Köpke T(2001)Urine based markers of urological malignancy J Urol 165 600-611

[8] Görge T(2003)Tumor markers in the diagnosis of primary bladder cancer. A systematic review J Urol 169 1975-1982

[9] Neumann J(2002)Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder Eur Urol 41 34-39

[10] Hertle L(2002)BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder Anticancer Res 22 1157-1160